OncoSec Opens New Headquarters and Research Facility in San Diego

Dec 17, 2015, 13:01 ET from OncoSec Medical Incorporated

SAN DIEGO, Dec. 17, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the Company consolidated its three previous offices into one new headquarters and research facility, developed by Alexandria Real Estate Equities, Inc., in Sorrento Mesa, San Diego. As a result of the Company's growth over the past year, OncoSec moved into a new office that houses over 50 employees and all of the Company's discovery research, clinical, and administrative activities under one roof.

"This is an exciting time for OncoSec as we join the Sorrento Mesa community and find a home in San Diego, a city that is on the cutting edge of the life science and biotech industries," said Punit Dhillon, President and CEO of OncoSec. "This move allows for greater efficiencies and interactions among our dedicated teams. Our new facility enhances our development capabilities and provides OncoSec with a base of operations that matches the magnitude of our ambitions."

"We are proud of the robust biotech industry and its incredible impact in California. It's encouraging to see another biotech company join and further strengthen the San Diego area, bringing jobs and economic vitality to the region," said Panorea Avdis, Director of the California Governor's Office of Business and Economic Development. "Not only are biotechs like OncoSec enhancing California's economy, they also play a greater role in advancing innovative technologies to provide better care and treatment for patients everywhere."

"OncoSec's stunning new headquarters was a result of a truly collaborative effort between the Company and Alexandria. We are thrilled to welcome them to our innovative tenant community," said Daniel Ryan, Executive Vice President, Regional Market Director (San Diego) and Strategic Operations of Alexandria Real Estate Equities, Inc. "The new facility provides OncoSec with a sustainable and environmentally friendly space that accommodates growth and enhances their R&D operations. We look forward to continuing to serve OncoSec's facility needs and support its efforts developing targeted cancer therapies."

The new facility, located at 5820 Nancy Ridge Drive, was built with environmental and green features in mind to reduce the Company's carbon footprint. The 34,000 square foot building features recycled materials, drought-tolerant vegetation, and a recycled water irrigation system, which will lower the water consumption impact and create an environment prepared to thrive in Southern California's current drought conditions.

OncoSec's research facility also integrates approximately 15,000 square feet of laboratory space with state-of-the-art equipment required for Discovery Research activities. The design approach incorporates laboratory benches, specialized rooms, and equipment strategically positioned to maximize workflow, provide sufficient ambulatory space, and minimize potential disruption to research.

About OncoSec Medical Incorporated

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.

Contact:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com

 

Photo - http://photos.prnewswire.com/prnh/20151217/296971

Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO

 

SOURCE OncoSec Medical Incorporated



RELATED LINKS

http://www.oncosec.com